Abstract
Cannabinoid receptors, belonging to the superfamily of G-protein coupled receptors, play a major role in pathophysiology of a wide range of disparate diseases. Cannabinoid CB2 receptor, which mainly locates in peripheral tissues, represents as a promising drug target for the treatment of pain, osteoporosis, liver disorders, and so on without serious CNS side effects. In the past decades, the identification and optimization of selective ligands for the CB2 receptor has been a major objective in drug discovery. In the present review, we describe recent advances in the development of novel chemotypes of the CB2 receptor selective ligands, and give a simple discussion for the corresponding structureactivity relationships of them.
Keywords: Cannabinoid receptors, CB2, GPCRs, selective ligand, structure-activity relationship.
Mini-Reviews in Medicinal Chemistry
Title:Latest Progress in the Identification of Novel Synthetic Ligands for the Cannabinoid CB2 Receptor
Volume: 14 Issue: 5
Author(s): Shuang Han, Jiong-Jiong Chen and Jian-Zhong Chen
Affiliation:
Keywords: Cannabinoid receptors, CB2, GPCRs, selective ligand, structure-activity relationship.
Abstract: Cannabinoid receptors, belonging to the superfamily of G-protein coupled receptors, play a major role in pathophysiology of a wide range of disparate diseases. Cannabinoid CB2 receptor, which mainly locates in peripheral tissues, represents as a promising drug target for the treatment of pain, osteoporosis, liver disorders, and so on without serious CNS side effects. In the past decades, the identification and optimization of selective ligands for the CB2 receptor has been a major objective in drug discovery. In the present review, we describe recent advances in the development of novel chemotypes of the CB2 receptor selective ligands, and give a simple discussion for the corresponding structureactivity relationships of them.
Export Options
About this article
Cite this article as:
Han Shuang, Chen Jiong-Jiong and Chen Jian-Zhong, Latest Progress in the Identification of Novel Synthetic Ligands for the Cannabinoid CB2 Receptor, Mini-Reviews in Medicinal Chemistry 2014; 14 (5) . https://dx.doi.org/10.2174/1389557514666140428105753
DOI https://dx.doi.org/10.2174/1389557514666140428105753 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphingolipids as Targets for Microbial Infections
Mini-Reviews in Medicinal Chemistry NMR Structural Studies of Human Cellular Prion Proteins
Current Topics in Medicinal Chemistry Competitive Gly/NMDA Receptor Antagonists
Current Topics in Medicinal Chemistry FTIR Spectroscopy Analysis can Highlight Induced Damage in Neuronallike Cells and Bio-protective Effectiveness of Agmatine
Current Metabolomics Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders
Current Alzheimer Research Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Meet Our Editorial Board Member:
Current Alzheimer Research Microencapsulation: The Emerging Role of Microfluidics
Micro and Nanosystems Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Blockade of Ser16-Hsp20 Phosphorylation Attenuates Neuroprotection Dependent Upon Bcl-2 and Bax
Current Neurovascular Research Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
CNS & Neurological Disorders - Drug Targets Parkinson´s and Alzheimer´s Diseases and Natural Products: Pathologies and Medication of the New Times
Current Neuropharmacology Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies
Current Pharmaceutical Design Molecular Insight into the Crosstalk of UPS Components and Alzheimer’s Disease
Current Protein & Peptide Science Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Retraction Notice: Potential Application of Venom Proteins in Designing of Medicines for Treating Human Neurodegenerative Disorders
Protein & Peptide Letters Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Current Neuropharmacology Mitochondrial Toxins in Basal Ganglia Disorders: From Animal Models to Therapeutic Strategies
Current Neuropharmacology The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Hyper-Homocysteinemia Alters Amyloid Peptide-Clusterin Interactions and Neuroglial Network Morphology and Function in the Caudate After Intrastriatal Injection of Amyloid Peptides
Current Alzheimer Research